RVRC — what changed in the latest 10-Q
A section-by-section comparison of RVRC's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-08-13 vs the prior 10-Q · 2026-05-14
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +6 | −6 | ~10 | 31 |
| Market risk (Item 3) | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Controls & procedures | Text added/removed | 0 | 0 | ~2 | 0 |
| Legal proceedings | No paragraph-level changes | 0 | 0 | 0 | 1 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Not shown (absent or not faithfully extractable): Risk factors, Other information
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-08-13
In March 2026, the Company submitted an application to the Israel Innovation Authority for non-dilutive funding support related to the Nano-Mupirocin program. On May 28, 2026, the Company was notified that the application was not approved in the current review cycle. In its written decision, the Res…
The Company’s research and development expenses totaled $443 thousand for the three months period ended June 30, 2026, representing an increase of $52 thousand, or 13.3%, compared to the Company’s research and development expenses of $391 thousand for the same period in 2025. For the six months peri…
The Company’s general and administrative expenses totaled $289 thousand for the three months period ended June 30, 2026, representing a decrease of $258 thousand, or 47.2%, compared to the Company’s general and administrative expenses of $547 thousand for the same period in 2025. For the six months …
As a result of the foregoing, the Company’s operating loss totaled $732 thousand for the three months period ended June 30, 2026, representing a decrease of $206 thousand, or 22.0%, compared to the Company’s operating loss of $938 thousand for the same period in 2025. For the six months period ended…
We recognized financing expenses, net of $16 thousand for the three months period ended June 30, 2026, compared to financing expenses, net, of $101 thousand for the same period in 2025, and financing expenses, net of $2 thousand for the six months period ended June 30, 2026, compared to financing in…
Text removed vs the prior filing · source: 10-Q · 2026-05-14
In March 2026, , we submitted an application to the Israel Innovation Authority for non-dilutive funding support related to the Nano-Mupirocin program. The application is under review, and there can be no assurance that the grant will be approved or that any funding will be received. No amounts have…
The Company’s research and development expenses totaled $473,000 for the three months period ended March 31, 2026, representing an increase of $255,000, or 116.9%, compared to the Company’s research and development expenses of $218,000 for the same period in 2025. The research and development expens…
The Company’s general and administrative expenses totaled $266,000 for the three months period ended March 31, 2026, representing a decrease of $253,000, or 48.7%, compared to the Company’s general and administrative expenses of $519,000 for the same period in 2025. The decrease was primarily attrib…
As a result of the foregoing, The Company’s operating loss totaled $739,000 for the three months period ended March 31, 2026, representing an increase of $2,000, or 0.2%, compared to the Company’s operating loss of $737,000 for the same period in 2025.
We recognized financing income, net of $14,000 for the three months period ended March 31, 2026, compared to $103,000 for the same period in 2025. The decrease in financing income, net, was due to lower interest income from bank deposits during the three months period ended March 31, 2026 compared t…
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice